Search for content, post, videos

2A Pharma raises SEK 27 million


The Swedish/Danish biotech company 2A Pharma has closed its first financing round and has been granted an exclusive, worldwide license from Medigene for its adeno-associated virus like particles (AAVLPs) technology.

2A Pharma AB, based in Malmö, Sweden with research facilities in Aalborg, Denmark, aims to develop novel, cost effective vaccines and therapeutics based on Medigene AG’s AAVLP technology which was exclusively in-licensed by 2A Pharma AB in December 2016. The company’s first financing round of SEK 27 million, closed in December 2016, provides sufficient funding to complete phase I clinical trials of the lead drug candidate.

“We are extremely pleased with the support we have received from our investors and the progress the team has achieved in a very short period. We believe we have tremendous opportunities to develop the company and its products, both internally and with partners. Our initial focus is to maintain an aggressive schedule for our first project to enable us to start clinical trials in 2018. This follows our strategy at Aalborg University to take science out where it makes a difference,” said Prof. Dr. Søren Nielsen, CEO of 2A Pharma.